Abstract
The association between ABCB1/MDR1 C3435T polymorphism and colorectal cancer has been evaluated. However, the results of these studies on the association remain inconsistent. To derive a more precise estimation of the relationship, a meta-analysis was performed. A comprehensive search was conducted to identify the eligible studies of ABCB1/MDR1 C3435T polymorphism and colorectal cancer risk. Summary odds ratios (OR) and 95 % confidence interval (CI) for ABCB1/MDR1 C3435T polymorphism and colorectal cancer were calculated. Statistical analysis was performed with the Stata (Version 12.0). Thirteen case–control studies, a total of 11,339 persons including 5,485 cases and 5,854 controls, met the included criteria and thus were selected. Collectively, the results of the present study suggest that there were no significant associations of ABCB1/MDR1 C3435T polymorphism with colorectal cancer observed for all comparison models. In the subgroup analysis, the same results were detected for both Caucasian and Asian populations. The results of this meta-analysis suggest that ABCB1/MDR1 C3435T polymorphism might be not related to colorectal cancer susceptibility.
Similar content being viewed by others
References
Lee JJ, Chu E. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Clin Colorectal Cancer. 2007;7:16–20.
Huxley RR, Ansary-Moghaddam A, Clifton P. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009;125:71–80.
Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. AAPS J. 2005;7(1):E1–5.
Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet. 1996;5(10):1649–55.
Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal. 2011;23(7):1119–27.
Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 2005;5:457–68.
Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein. Trends Biochem Sci. 2000;25(1):1–6.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473–8.
Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J. P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol. 2004;31:758–63.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol. 2005;61:389–94.
Lee BI, Choi KY, Lee KM, Chung WC, Kim BW, et al. Is C3435T polymorphism of MDR1 related to inflammatory bowel disease or colorectal cancer in Korean? Korean J Gastroenterol. 2006;47:22–9.
Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006;21:126–32.
Bae SY, Choi SK, Kim KR, Park CS, Lee SK, et al. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci. 2006;97:774–9.
Osswald E, Johne A, Laschinski G, Arjomand-Nahad F, Malzahn U, et al. Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol. 2007;63:9–16.
Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, et al. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 2008;134:317–22.
Potocnik U, Glavac D, Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet. 2008;183:28–34.
Andersen V, Stergaard M, Christensen J, et al. Polymorphisms in the xenobiotic transporter Multidrug Resistance1(MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:1–11.
Panczyk M, Balcerczak E, Piaskowski S, et al. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis. 2009;24:895–905.
Khedri A, Nejat-Shokouhi A, Salek R, et al. Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep. 2011;38:2939–43.
Sainz J, Rudolph A, Hein R, et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. 2011;18:265–76.
Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, et al. A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One. 2012;7(3):e32784.
Ozhan G, Kara M, Sari FM, Yanar HT, Ercan G, et al. Associations between the functional polymorphisms in the ABCB1 transporter gene and colorectal cancer risk: a case–control study in Turkish population. Toxicol Mech Methods. 2013;15:1–5.
Petrova DT, Nedeva P, Maslyankov S, et al. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 2008;134:317–22.
Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010;10:62–9.
George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, et al. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer. 2009;9:161–5.
Chen S, Huo X, Lin Y, Ban H, Li W, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213:140–5.
Paule B, Castagne V, Picard V, Saffroy R, Adam R, et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol. 2010;27:1066–72.
Krupoves A, Seidman EG, Mack D, Israel D, Morgan K, et al. Associations between ABCB1/MDR1 gene polymorphisms and Crohn’s disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis. 2009;15:900–8.
Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998;41(1):47–53.
Conflicts of interest
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, L., Li, K., Li, W. et al. Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility. Tumor Biol. 34, 1949–1957 (2013). https://doi.org/10.1007/s13277-013-0740-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-0740-0